1.Humidified Nebulizer to Prevent Tracheostomy Cannula From Obstruction During the COVID-19 Pandemic
Ki Ju CHO ; Min Ji KIM ; Yoon Se LEE ; Minsu KWON ; Yonghan KIM ; Young Ho JUNG ; Seung-Ho CHOI ; Soon Yuhl NAM
Journal of the Korean Society of Laryngology Phoniatrics and Logopedics 2024;35(2):58-64
Background and Objectives:
Obstruction of tracheostomy cannula (T-cannula) may result in devastating results, such as hypoxic brain injury and even death. Since the recent coronavirus disease 2019 (COVID-19) outbreak, nebulizing for humidification to prevent tracheostomy cannula obstruction has been controversial due to concerns about viral spreading through aerosol. The present study evaluated the risk of cannula obstruction and thereby suggest an adequate prevention method during the COVID-19 pandemic.Materials and Method From January 2020 to October 2020, we retrospectively analyzed medical records of patients who underwent tracheostomy at the Department of Otolaryngology at Asan Medical Center, Seoul, Korea. The frequency of tracheostomy tube obstruction was compared in patients who were or were not nebulized. Additional clinical variates included patient’s sex, age, smoking history, medical history, and current medical history were evaluated.
Results:
Enrolled 226 patients were divided into obstruction (n=62) and non-obstruction group (n=164). T-cannula obstruction was related to period of tracheostomy, smoking history, pulmonary diseases, and nebulized use. In Cox proportional hazards analysis, ex-smoking (hazard ratio [HR]=1.962, p=0.033), current smoking (HR=2.108, p=0.027), and pulmonary diseases (HR=1.740, p=0.038) were related to T-cannula obstruction. When other factors were corrected, the risk of tracheostomy obstruction was significantly decreased in the nebulized group (HR=0.216, p<0.001). Mortality rate of this group was affected by only pulmonary diseases.
Conclusion
Nebulizer can be applied safely and helps to avoid the risk of T-cannula obstruction.
2.Long-term risk of all-cause mortality in live kidney donors: a matched cohort study
Eunjeong KANG ; Sehoon PARK ; Jina PARK ; Yaerim KIM ; Minsu PARK ; Kwangsoo KIM ; Hyo Jeong KIM ; Miyeun HAN ; Jang-Hee CHO ; Jung Pyo LEE ; Sik LEE ; Soo Wan KIM ; Sang Min PARK ; Dong-Wan CHAE ; Ho Jun CHIN ; Yong Chul KIM ; Yon Su KIM ; Insun CHOI ; Hajeong LEE
Kidney Research and Clinical Practice 2022;41(1):102-113
Long-term outcomes of live kidney donors remain controversial, although this information is crucial for selecting potential donors. Thus, this study compared the long-term risk of all-cause mortality between live kidney donors and healthy control. Methods: We performed a retrospective cohort study including donors from seven tertiary hospitals in South Korea. Persons who underwent voluntary health screening were included as controls. We created a matched control group considering age, sex, era, body mass index, baseline hypertension, diabetes, estimated glomerular filtration rate, and dipstick albuminuria. The study outcome was progression to end-stage kidney disease (ESKD), and all-cause mortality as identified in the linked claims database. Results: We screened 1,878 kidney donors and 78,115 health screening examinees from 2003 to 2016. After matching, 1,701 persons remained in each group. The median age of the matched study subjects was 44 years, and 46.6% were male. Among the study subjects, 2.7% and 16.6% had underlying diabetes and hypertension, respectively. There were no ESKD events in the matched donor and control groups. There were 24 (1.4%) and 12 mortality cases (0.7%) in the matched donor and control groups, respectively. In the age-sex adjusted model, the risk for all-cause mortality was significantly higher in the donor group than in the control group. However, the significance was not retained after socioeconomic status was included as a covariate (adjusted hazard ratio, 1.82; 95% confidence interval, 0.87–3.80). Conclusion: All-cause mortality was similar in live kidney donors and matched non-donor healthy controls with similar health status and socioeconomic status in the Korean population.
3.Influenza Vaccine Effectiveness in Children at the Emergency Department during the 2018-2019 Season: the First Season School-aged Children Were Included in the Korean Influenza National Immunization Program
Yoonsun YOON ; Joon-sik CHOI ; MiRan PARK ; Hyun CHO ; Minsu PARK ; Hee Jae HUH ; Yae-Jean KIM ; Meong Hi SON
Journal of Korean Medical Science 2021;36(10):e71-
Background:
For the 2018–2019 season, the national influenza immunization program expanded to cover children aged from 6 months to 12 years in Korea. This study aimed to analyze vaccine effectiveness (VE) against influenza in children visiting the pediatric emergency room at a tertiary hospital during the 2018-2019 season.
Methods:
Patients tested for influenza antigens from October 1st 2018 to May 31st 2019 at the pediatric emergency room of Samsung Medical Center were included. Patients' influenza antigen test results, influenza vaccination history, and underlying medical conditions were reviewed retrospectively. VE was estimated from the test-negative design study.
Results:
Among the 2,901 visits with influenza test results 1,692 visits of 1,417 patients were included for analysis. Among these 1,417 patients, 285 (20.1%) were positive (influenza A, n = 211, 74.0%; influenza B, n = 74, 26.0%). The VE in all patients was 36.4% (95% confidence interval [CI], 13.9 to 53.1). The VE for influenza A was 37.6% (95% CI, 12.6 to 55.5) and VE for influenza B was 24.0% (−38.5 to 58.3). The VE in the age group 6 months to 12 years was significant with a value of 35.6% (95% CI, 10.5 to 53.7); it was not statistically significant in the age group 13 to 18 years. In a multivariate logistic regression model, patients who received an influenza vaccination were less likely to get influenza infection (OR, 0.6; 95% CI, 0.4 to 0.8; P = 0.001), with significant confounding factors such as age group 13 to 18 years (OR, 0.5; 95% CI, 0.3 to 0.8; P = 0.003) and underlying hematology-oncology disease (OR, 0.3;95% CI, 0.1 to 0.6; P = 0.002).
Conclusion
We report moderate effectiveness of influenza vaccination in previously healthy children aged from 6 months to 12 years in the 2018-2019 season.
4.Clinical Significance of Acute Kidney Injury in Lung Cancer Patients
Semin CHO ; Eunjeong KANG ; Ji Eun KIM ; U KANG ; Hee Gyung KANG ; Minsu PARK ; Kwangsoo KIM ; Dong Ki KIM ; Kwon Wook JOO ; Yon Su KIM ; Hyung-Jin YOON ; Hajeong LEE
Cancer Research and Treatment 2021;53(4):1015-1023
Purpose:
Acute kidney injury (AKI) in cancer patients is associated with increased morbidity and mortality. The incidence of AKI in lung cancer seems to be relatively higher compared with other solid organ malignancies, although its impact on patient outcomes remains unclear.
Materials and Methods:
The patients newly diagnosed with lung cancer from 2004 to 2013 were enrolled in this retrospective cohort study. The patients were categorized according to the presence and severity of AKI. We compared all-cause mortality and long-term renal outcome according to AKI stage.
Results:
A total of 3,202 patients were included in the final analysis. AKI occurred in 1,783 (55.7%) patients during the follow-up period, with the majority having mild AKI stage 1 (75.8%). During the follow-up of 2.6±2.2 years, total 1,251 patients (53.7%) were died and 5-year survival rate was 46.9%. We found that both AKI development and severity were independent risk factors for all-cause mortality in lung cancer patients, even after adjustment for lung cancer-specific variables including the stage or pathological type. In addition, patients suffered from more severe AKI tend to encounter de novo chronic kidney disease development, worsening kidney function, and end-stage kidney disease progression.
Conclusion
In this study, more than half of the lung cancer patients experienced AKI during their diagnosis and treatment period. Moreover, AKI occurrence and more advanced AKI were associated with a higher mortality risk and adverse kidney outcomes.
5.Influenza Vaccine Effectiveness in Children at the Emergency Department during the 2018-2019 Season: the First Season School-aged Children Were Included in the Korean Influenza National Immunization Program
Yoonsun YOON ; Joon-sik CHOI ; MiRan PARK ; Hyun CHO ; Minsu PARK ; Hee Jae HUH ; Yae-Jean KIM ; Meong Hi SON
Journal of Korean Medical Science 2021;36(10):e71-
Background:
For the 2018–2019 season, the national influenza immunization program expanded to cover children aged from 6 months to 12 years in Korea. This study aimed to analyze vaccine effectiveness (VE) against influenza in children visiting the pediatric emergency room at a tertiary hospital during the 2018-2019 season.
Methods:
Patients tested for influenza antigens from October 1st 2018 to May 31st 2019 at the pediatric emergency room of Samsung Medical Center were included. Patients' influenza antigen test results, influenza vaccination history, and underlying medical conditions were reviewed retrospectively. VE was estimated from the test-negative design study.
Results:
Among the 2,901 visits with influenza test results 1,692 visits of 1,417 patients were included for analysis. Among these 1,417 patients, 285 (20.1%) were positive (influenza A, n = 211, 74.0%; influenza B, n = 74, 26.0%). The VE in all patients was 36.4% (95% confidence interval [CI], 13.9 to 53.1). The VE for influenza A was 37.6% (95% CI, 12.6 to 55.5) and VE for influenza B was 24.0% (−38.5 to 58.3). The VE in the age group 6 months to 12 years was significant with a value of 35.6% (95% CI, 10.5 to 53.7); it was not statistically significant in the age group 13 to 18 years. In a multivariate logistic regression model, patients who received an influenza vaccination were less likely to get influenza infection (OR, 0.6; 95% CI, 0.4 to 0.8; P = 0.001), with significant confounding factors such as age group 13 to 18 years (OR, 0.5; 95% CI, 0.3 to 0.8; P = 0.003) and underlying hematology-oncology disease (OR, 0.3;95% CI, 0.1 to 0.6; P = 0.002).
Conclusion
We report moderate effectiveness of influenza vaccination in previously healthy children aged from 6 months to 12 years in the 2018-2019 season.
6.Metabolic risks in living kidney donors in South Korea
Eunjeong KANG ; Jina PARK ; Hyo Jeong KIM ; Sehoon PARK ; Minsu PARK ; Yaerim KIM ; Kwangsoo KIM ; Sang Min PARK ; Dong-Wan CHAE ; Ho Jun CHIN ; Jung Pyo LEE ; Sik LEE ; Soo Wan KIM ; Jang-Hee CHO ; Miyeun HAN ; Yong Chul KIM ; Yon Su KIM ; Insun CHOI ; Hajeong LEE
Kidney Research and Clinical Practice 2021;40(4):645-659
Background:
Considering the growing prevalence of Western lifestyles and related chronic diseases occurring in South Korea, this study aimed to explore the progression of metabolic risk factors in living kidney donors compared to a control group.
Methods:
This study enrolled living kidney donors from seven hospitals from 1982 to 2016. The controls were individuals that voluntarily received health check-ups from 1995 to 2016 that were matched with donors according to age, sex, diabetes status, baseline estimated glomerular filtration rate, and date of the medical record. Data on hyperuricemia, hypertension, hypercholesterolemia, and overweight/obesity were collected to determine metabolic risks. The proportion of individuals with three or more metabolic risk factors was evaluated. Logistic regressions with interaction terms between the medical record date and donor status were used to compare the trends in metabolic risks over time in the two groups.
Results:
A total of 2,018 living kidney donors and matched non-donors were included. The median age was 44.0 years (interquartile range, 34.0–51.0 years) and 54% were women. The living kidney donors showed a lower absolute prevalence for all metabolic risk factors, except for those that were overweight/obese, than the non-donors. The proportion of subjects that were overweight/obese was consistently higher over time in the donor group. The changes over time in the prevalence of each metabolic risk were not significantly different between groups, except for a lower prevalence of metabolic risk factors ≥ 3 in donors.
Conclusion
Over time, metabolic risks in living kidney donors are generally the same as in non-donors, except for a lower prevalence of metabolic risk factors ≥ 3 in donors.
7.Effect of Prostaglandin Analogues on Central Corneal Thickness:3-Year Follow-up Results
Minsu JANG ; Kyung Eun KANG ; Byung Joo CHO
Korean Journal of Ophthalmology 2020;34(5):347-352
Purpose:
To evaluate the effects of each subgroup of prostaglandin analogues (PGAs) on central corneal thickness (CCT) in patients with normal tension glaucoma (NTG).
Methods:
We retrospectively reviewed 55 eyes of 55 patients with NTG who were receiving PGA therapy. Patients who were treated with 0.005% latanoprost (16 eyes), 0.0015% tafluprost (16 eyes), or 0.004% travoprost (23 eyes) monotherapy were included. CCT assessments were performed at baseline and 1, 2, and 3 years after initiation of treatment.
Results:
In the NTG group, the mean CCT showed a decreasing trend, and there was a significant difference in mean CCT at 1, 2, and 3 years compared with baseline (baseline, 538.16 ± 32.14; 1 year, 526.55 ± 37.30 µm [p = 0.00]; 2 years, 521.67 ± 36.79 µm [p = 0.00]; 3 years, 520.43 ± 36.88 µm [p = 0.00]). The reduction of CCT was confirmed by subgroup analysis. In the 0.005% latanoprost group, mean CCT was decreased at 1 year (p = 0.11), 2 years (p = 0.00), and 3 years (p = 0.02). In the 0.0015% ta-fluprost group and the 0.004% travoprost group, mean CCT was also significantly decreased at all years (p = 0.00). No statisti-cal difference was observed between the NTG subgroups (p = 0.06).
Conclusions
Topical therapy with PGAs appeared to cause a significant decrease in CCT reduction in patients with NTG. A long-term follow-up study including more participants is needed.
8.Role of Carotid Artery Stenting in Prevention of Stroke for Asymptomatic Carotid Stenosis: Bayesian Cross-Design and Network Meta-Analyses
Jae Hyung ROH ; Hyun Jun CHO ; Jae Hwan LEE ; Yongku KIM ; Yeongwoo PARK ; Jae Hyeong PARK ; Hee Soon PARK ; Minsu KIM ; Hyang Gon JIN ; Yeji CHEON ; In Whan SEONG
Korean Circulation Journal 2020;50(4):330-342
BACKGROUND AND OBJECTIVES: There is insufficient evidence regarding the optimal treatment for asymptomatic carotid stenosis.METHODS: Bayesian cross-design and network meta-analyses were performed to compare the safety and efficacy among carotid artery stenting (CAS), carotid endarterectomy (CEA), and medical treatment (MT). We identified 18 studies (4 randomized controlled trials [RCTs] and 14 nonrandomized, comparative studies [NRCSs]) comparing CAS with CEA, and 4 RCTs comparing CEA with MT from MEDLINE, Cochrane Library, and Embase databases.RESULTS: The risk for periprocedural stroke tended to increase in CAS, compared to CEA (odds ratio [OR], 1.86; 95% credible interval [CrI], 0.62–4.54). However, estimates for periprocedural myocardial infarction (MI) were quite heterogeneous in RCTs and NRCSs. Despite a trend of decreased risk with CAS in RCTs (OR, 0.70; 95% CrI, 0.27–1.24), the risk was similar in NRCSs (OR, 1.02; 95% CrI, 0.87–1.18). In indirect comparisons of MT and CAS, MT showed a tendency to have a higher risk for the composite of periprocedural death, stroke, MI, or nonperiprocedural ipsilateral stroke (OR, 1.30; 95% CrI, 0.74–2.73). Analyses of study characteristics showed that CEA-versus-MT studies took place about 10-year earlier than CEA-versus-CAS studies.CONCLUSIONS: A similar risk for periprocedural MI between CEA and CAS in NRCSs suggested that concerns about periprocedural MI accompanied by CEA might not matter in real-world practice when preoperative evaluation and management are working. Maybe the benefits of CAS over MT have been overestimated considering advances in medical therapy within10-year gap between CEA-versus-MT and CEA-versus-CAS studies.
Carotid Arteries
;
Carotid Stenosis
;
Endarterectomy, Carotid
;
Myocardial Infarction
;
Stents
;
Stroke
9.Role of Carotid Artery Stenting in Prevention of Stroke for Asymptomatic Carotid Stenosis: Bayesian Cross-Design and Network Meta-Analyses
Jae Hyung ROH ; Hyun Jun CHO ; Jae Hwan LEE ; Yongku KIM ; Yeongwoo PARK ; Jae Hyeong PARK ; Hee Soon PARK ; Minsu KIM ; Hyang Gon JIN ; Yeji CHEON ; In Whan SEONG
Korean Circulation Journal 2020;50(4):330-342
BACKGROUND AND OBJECTIVES:
There is insufficient evidence regarding the optimal treatment for asymptomatic carotid stenosis.
METHODS:
Bayesian cross-design and network meta-analyses were performed to compare the safety and efficacy among carotid artery stenting (CAS), carotid endarterectomy (CEA), and medical treatment (MT). We identified 18 studies (4 randomized controlled trials [RCTs] and 14 nonrandomized, comparative studies [NRCSs]) comparing CAS with CEA, and 4 RCTs comparing CEA with MT from MEDLINE, Cochrane Library, and Embase databases.
RESULTS:
The risk for periprocedural stroke tended to increase in CAS, compared to CEA (odds ratio [OR], 1.86; 95% credible interval [CrI], 0.62–4.54). However, estimates for periprocedural myocardial infarction (MI) were quite heterogeneous in RCTs and NRCSs. Despite a trend of decreased risk with CAS in RCTs (OR, 0.70; 95% CrI, 0.27–1.24), the risk was similar in NRCSs (OR, 1.02; 95% CrI, 0.87–1.18). In indirect comparisons of MT and CAS, MT showed a tendency to have a higher risk for the composite of periprocedural death, stroke, MI, or nonperiprocedural ipsilateral stroke (OR, 1.30; 95% CrI, 0.74–2.73). Analyses of study characteristics showed that CEA-versus-MT studies took place about 10-year earlier than CEA-versus-CAS studies.
CONCLUSIONS
A similar risk for periprocedural MI between CEA and CAS in NRCSs suggested that concerns about periprocedural MI accompanied by CEA might not matter in real-world practice when preoperative evaluation and management are working. Maybe the benefits of CAS over MT have been overestimated considering advances in medical therapy within10-year gap between CEA-versus-MT and CEA-versus-CAS studies.
10.Predictive Model for Differential Diagnosis of Inflammatory Papular Dermatoses of the Face
Bo Ri KIM ; Minsu KIM ; Chong Won CHOI ; Soyun CHO ; Sang Woong YOUN
Annals of Dermatology 2020;32(4):298-305
Background:
The clinical features of inflammatory papulardermatoses of the face are very similar. Their clinical manifestationshave been described on the basis of a small numberof case reports and are not specific.
Objective:
This studyaimed to use computer-aided image analysis (CAIA) to comparethe clinical features and parameters of inflammatorypapular dermatoses of the face and to develop a formalizeddiagnostic algorithm based on the significant findings.
Methods:
The study included clinicopathologically confirmedinflammatory papular dermatoses of the face: 8 casesof eosinophilic pustular folliculitis (EPF), 13 of granulomatousperiorificial dermatitis-lupus miliaris disseminatusfaciei (GPD-LMDF) complex, 41 of granulomatous rosacea-papulopustular rosacea complex (GR-PPR) complex,and 4 of folliculitis. Clinical features were evaluated, andarea density of papular lesions was quantitatively measuredwith CAIA. Based on these variables, we developed a predictivemodel for differential diagnosis using classificationand regression tree analysis.
Results:
The EPF group showedlesion asymmetry and annular clusters of papules in all cases.The GPD-LMDF complex group had significantly higher perioculardensity. The GR-PPR complex group showed a higherarea density of unilateral cheek papules and the highest total area density. According to the predictive model, 3 variableswere used for differential diagnosis of the 4 diseasegroups, and each group was diagnosed with a predictedprobability of 67%∼100%.
Conclusion
We statisticallyconfirmed the distinct clinical features of inflammatory papulardermatoses of the face and proposed a diagnostic algorithmfor clinical diagnosis.

Result Analysis
Print
Save
E-mail